Eagle pharmaceutical stock
WebApr 5, 2024 · Eagle Pharmaceuticals (NASDAQ:EGRX) has a market capitalization of $339.17 million and generates $316.61 million in revenue each year. The specialty … WebApr 8, 2024 · Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central …
Eagle pharmaceutical stock
Did you know?
WebGet the latest Eagle Pharmaceuticals Inc (EGRX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and … WebNov 11, 2016 · Under the terms of the stock purchase agreement, Eagle will pay approximately $30 million at closing, $27.3 million of which will be paid in cash and $2.7 million of which will be paid in Eagle ...
WebEagle Pharmaceuticals (EGRX) Q3 Earnings and Revenues Beat Estimates Zacks - Mon Nov 7, 2024 . Eagle Pharmaceuticals (EGRX) delivered earnings and revenue … WebMar 9, 2024 · Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results. 3/13/23. • Q4 2024 net income was $0.63 per basic and $0.62 per diluted share and …
WebDec 23, 2024 · As of December 22, 2024, Eagle Pharmaceuticals Inc had a $388.8 million market capitalization, putting it in the 52nd percentile of companies in the Pharmaceuticals industry. Currently, Eagle Pharmaceuticals Inc’s price-earnings ratio is 17.8. Eagle Pharmaceuticals Inc’s trailing 12-month revenue is $298.2 million with a 7.1% profit … WebApr 4, 2024 · The latest price target for Eagle Pharmaceuticals ( NASDAQ: EGRX) was reported by Cantor Fitzgerald on Monday, March 2, 2024. The analyst firm set a price target for 46.00 expecting EGRX to rise ...
WebFeb 6, 2024 · Lugo covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Collegium Pharmaceutical, and Adamas Pharmaceuticals. Currently, the analyst consensus on Eagle Pharmaceuticals is a Moderate Buy with an average price target of $50.50.
WebMar 24, 2024 · Eagle Pharmaceuticals to Host Third Quarter 2024 Financial Results on November 7, 2024. WOODCLIFF LAKE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- … cssiw wales standardsWebMar 24, 2024 · Eagle Pharmaceuticals, Inc. is a pharmaceutical company. The Company's products include Ryanodex, Bendeka, Belrapzo, Treakisym, Pemfexy, Barhemsys and Byfavo. Ryanodex is used for malignant hyperthermia. EP-4104 Ryanodex (dantrolene sodium) is used for the treatment of organophosphate exposure. Belrapzo, … earl of derby buryWebMar 9, 2024 · Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results. 3/13/23. • Q4 2024 net income was $0.63 per basic and $0.62 per diluted share and adjusted non-GAAP net income was $1.11 per basic and $1.10 per diluted share 1 • Total revenue for Q4 2024 was $60.7 million, compared to $42.3 million in Q4 2024 • FY 2024 … earl of derbyWebApr 12, 2024 · Eagle Pharmaceuticals Stock Up 1.2 %. EGRX opened at $31.37 on Wednesday. The firm has a 50 day moving average price of $28.88 and a 200 day moving average price of $30.69. The company has a ... earl of derby pub cambridgeWebReal time Eagle Pharmaceuticals (EGRX) stock price quote, stock graph, news & analysis. earl of derby terraceWebNov 14, 2024 · WOODCLIFF LAKE, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) announced today that the U.S. Food and Drug Administration (“FDA”) has accepted its investigational new drug (“IND”) application for CAL02, a novel first-in-class broad-spectrum anti-virulence agent … earl of darlingtonWebApr 10, 2024 · Eagle Pharma stock halted on news that heat stroke drug failed to get FDA approval Jul. 26, 2024 at 12:36 p.m. ET by Emma Court 15 companies with outsized … cssiw reports wales